UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 1 of 66  A POSTMARKETING, MUL TICENTER, LONGITUDIN AL, 
PROSPECTIVE, PHARMAC OKINETIC, PHASE 1B S TUDY IN 
PREGNANT WOMEN WITH CHRONIC INFLAMMATORY  
DISEASES TREATED WIT H CIMZIA® 
(CERTOLIZUMAB  PEGOL)  
 
PROTOCOL UP0085  
PHASE 1B  
 
SHORT TITLE:  
A postmarketing, multicenter, pharmacokinetic study in pregnant women with chronic 
inflammatory diseases treated with certolizumab pegol  
Sponsor:  
UCB Biopharma SRL  
Allée d e la Recherche 60  
1070 Brussels  
BELGIUM  
Regulatory agency identifying number(s):  
EudraCT Number:  2019 -003410 -13 
IND Number:  11,197  
NCT Number:  Not yet assigned  
Confidential Material  
Confidential  
This document is the property of UCB and may not – in full  or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 2 of 66  PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE 
Document History  
Document  Date  Type of amendment  
Protocol Amendment 2  30 Aug 2022  Substantial  
Protocol Amendment 1.1 
(France)  01 Mar 2021  Substantial  
Protocol Amendment 1  29 Aug 2019  Substantial  
Original Protocol  31 Jul 2019  Not applicable  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 3 of 66  Amendment 2 ( 30 Aug 2022 )  
Overall Rationale for the Amendment  
The Sponsor wishes to clarify the adequate amount of data per participant which would classify the participant as  providing 
longitudinal data over the pregnancy and postpartum periods.  
Section # and Name  Description of Change  Brief Rationale  
Title Page  Previous text:  
UCB SPRL  
 
New text:  
UCB SRL  Updated with sponsor’s name change.  
Section  1.1, Synopsis   Previous text:  
Enrollment is anticipated until 
approximately 10 to 12 study participants 
have complete longitudinal data sets 
(defined  as a data set including all predose 
samples collected Q4W and postdose 
samples collected Q8W over the 
pregnancy period and at least 1 postpartum 
sample).  
 
New text:  Enrollment will occur until a 
minimum of 10 study participants have 
longitudinal data (defined as at least 4 
quantifiable predose and 2 quantifiable 
postdose PK samples during pregnancy 
and at least 1 quantifiable postpartum 
sample) over the study period.  To update the planned enrollment needed 
to provide a sufficient number of 
participants  with adequate data.  
Section  1.2, Schema  The post -partum period was changed to 
from 8 -13 weeks to 13 weeks.  Updated to align with the rest of the  
protocol.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 4 of 66  Section  4.1, Overall design   Previous text:  
The study will continue to enroll 
participants until approximately of 10 to 
12 complete individual longitudinal 
datasets are obtained. This is inclusive of 
PK samples (predose and postdose as 
defined in Section 1.1) obtained during the 
pregnancy along with  postpartum samples. 
Study enrollment may be stopped after the 
minimum number of participants is 
reached, or the study may continue to 
enroll beyond the minimum number of 
participants if cumulated PK data are not 
deemed sufficient to meet the primary 
objec tive. 
New text:  The study will enroll 
participants based on a minimum of 10 
study participants providing 
longitudinal data (defined as at least 4 
quantifiable predose and 2 quantifiable 
postdose PK samples during pregnancy 
and at least 1 quantifiable postp artum 
sample) over the study period. Study 
enrol lment may be stopped after the 
minimum number of participants is 
reached, or the study may continue to 
enroll beyond the minimum number of 
participants if cumulated study PK data 
are not deemed sufficient to meet the 
primary objective.  
 To update the planned enrollment needed 
to provide a sufficient number of 
participants with adequate data.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 5 of 66  Section  9.1, Definition of analysis sets   New text added: There will be 4 analysis 
sets for the study; the All Study 
Participants Screened Set, the Enrolled 
Set (ES), the Safety Set (SS) and the 
Pharmaco kinetic Per Protocol Set (PK -
PPS).  
The All Study Participants Screened Set 
will consist of all study participants who 
have signed the ICF and will include all 
participants who pass screening as well 
as screen failures. This will be the 
largest analysis se t. Updated to align with the most recent 
SAP amendment.  
Section  9.8, Sample size   Previous text: From these 15 evaluable 
participants, it is expected approximately 
10 to 12 complete individual longitudinal 
datasets will be collected.  
New text: These 15 evaluable 
participants are expected to provide the 
minimum of 10 study participants 
providing longitudinal data as defined 
in Section 4.1.  To up date the planned enrollment needed 
to provide a sufficient number of 
participants with adequate data.  
Section  9.3.3.1  , Adverse events  Previous text: All AEs will be coded using 
the Medical Dictionary for Regulatory 
Activities (MedDRA v19.1) and 
characterized as treatment -emergent 
according to the intake of CZP.  
New text: All AEs will be coded using 
the Medical Dictionary for Regulatory 
Activities (MedDRA v24.1  or higher ) 
and characterized as treatment -
emergent according to the intake of 
CZP.  Updated to align with the most recent 
SAP amendment.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 6 of 66  Throughout th e protocol  Minor typographical edits have been 
incorporated in the protocol.   
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 7 of 66  SERIOUS ADVERSE EVEN T REPORTING  
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World: +32 2 386 24 21  
US and Canada: +1 800 880 6949 or +1 866 890 3175  
Email  Global:  DS_ICT@ucb.com (for interventional clinical studies)  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 8 of 66  TABLE OF CONTENTS  
PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE  ................................ ...... 2 
SERIOUS ADVERSE EVEN T REPORTING  ................................ ................................ ..........  7 
1 PROTOCOL SUMMARY  ................................ ................................ ...............................  12 
1.1 Synopsis  ................................ ................................ ................................ ...........................  12 
1.2 Schema  ................................ ................................ ................................ .............................  15 
1.3 Schedule of Activities  ................................ ................................ ................................ ...... 16 
2 INTRODUCTION  ................................ ................................ ................................ ...........  20 
2.1 Study rationale  ................................ ................................ ................................ .................  20 
2.2 Background  ................................ ................................ ................................ ......................  20 
2.3 Benefit/risk assessment  ................................ ................................ ................................ .... 21 
3 OBJECTIVES AND ENDPO INTS  ................................ ................................ .................  22 
4 STUDY DESIGN  ................................ ................................ ................................ .............  22 
4.1 Overall design  ................................ ................................ ................................ ..................  22 
4.2 Scientific rationale for study design ................................ ................................ .................  24 
4.3 Justification for dose  ................................ ................................ ................................ ........  24 
4.4 End of study definition  ................................ ................................ ................................ ..... 24 
5 STUDY POPULATION  ................................ ................................ ................................ .. 25 
5.1 Inclus ion criteria  ................................ ................................ ................................ ..............  25 
Age   ................................ ................................ ................................ .....................  25 
Type of participant and disease characteristics  ................................ ................................ .... 25 
Sex   ................................ ................................ ................................ .....................  25 
Informed consent  ................................ ................................ ................................ .................  25 
5.2 Exclusion criteria  ................................ ................................ ................................ .............  26 
Medical conditions  ................................ ................................ ................................ ...............  26 
Prior/conc omitant therapy  ................................ ................................ ................................ .... 26 
Prior/concurrent clinical study experience  ................................ ................................ ..........  27 
Diagnostic assessments  ................................ ................................ ................................ ........  27 
5.3 Lifestyle restrictions  ................................ ................................ ................................ .........  27 
5.3.1  Meals and dietary restrictions  ................................ ................................ ..............  27 
5.3.2  Caffeine, alcohol, and tobacco  ................................ ................................ .............  27 
5.3.3  Activity  ................................ ................................ ................................ ................  27 
5.4 Screen fai lures  ................................ ................................ ................................ ..................  27 
6 STUDY TREATMENT  ................................ ................................ ................................ ... 27 
6.1 Treatment administered ................................ ................................ ................................ .... 28 
6.2 Preparation, handling, storage, and accountability requirements  ................................ .... 28 
6.3 Measures to minimize bias: Randomization and blinding  ................................ ...............  28 
6.4 Treatment compliance  ................................ ................................ ................................ ...... 28 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 9 of 66  6.5 Concomitant medication(s)/treatment(s) ................................ ................................ ..........  28 
6.5.1  Permitted concomitant treatments (medications and therapies)  ..........................  29 
6.5.2  Concomitant medications that lead to study withdrawal  ................................ ..... 29 
6.6 Dose modification  ................................ ................................ ................................ ............  29 
6.7 Treatment after the end of the study  ................................ ................................ ................  30 
7 DISCONTINUATION OF S TUDY MEDICATION AND PARTICIPANT 
DISCONTINUATION/WITH DRAWAL  ................................ ................................ ........  30 
7.1 Discontinuation of study medication  ................................ ................................ ...............  30 
7.1.1  Temporary discontinuation  ................................ ................................ ..................  30 
7.2 Participant discontinuation/withdrawal from the study  ................................ ...................  30 
7.3 Lost to follow up  ................................ ................................ ................................ ..............  31 
8 STUDY ASSESSMENTS AN D PROCEDURES  ................................ ...........................  31 
8.1 Efficacy assessments  ................................ ................................ ................................ ........  32 
8.2 Safety assessments  ................................ ................................ ................................ ...........  32 
8.2.1  Physical examination  ................................ ................................ ...........................  32 
8.2.2  Vital signs  ................................ ................................ ................................ ............  32 
8.2.3  Electrocardiograms  ................................ ................................ ..............................  33 
8.2.4  Clinical safety laboratory assessments  ................................ ................................  33 
8.2.5  Pregnancy outcome  ................................ ................................ ..............................  33 
8.3 Adverse events  ................................ ................................ ................................ .................  33 
8.3.1  Time period and frequency for collecting AE and SAE information  ..................  33 
8.3.2  Method of detecting AEs and SAEs  ................................ ................................ .... 34 
8.3.3  Follow -up of AEs and SAEs  ................................ ................................ ................  34 
8.3.4  Regulatory reporting requirements for SAEs  ................................ ......................  34 
8.3.5  Pregnancy  ................................ ................................ ................................ ............  34 
8.3.6  Adverse events of special interest  ................................ ................................ ........  34 
8.3.7  Disease -related events and/or disease -related outcomes not qualifying as AEs or 
SAEs  ................................ ................................ ................................ ....................  35 
8.4 Safety signal detection  ................................ ................................ ................................ ..... 36 
8.5 Treatment of overdose  ................................ ................................ ................................ ..... 36 
8.6 Pharmacokinetics  ................................ ................................ ................................ .............  36 
8.7 Pharmacodynamics  ................................ ................................ ................................ ..........  36 
8.8 Genetics  ................................ ................................ ................................ ............................  37 
8.9 Biomarkers  ................................ ................................ ................................ .......................  37 
8.9.1  Immunogenicity assessments  ................................ ................................ ...............  37 
9 STATISTICAL CONSIDER ATIONS  ................................ ................................ .............  37 
9.1 Definition of analysis sets  ................................ ................................ ................................  37 
9.2 General statistical considerations  ................................ ................................ .....................  37 
9.3 Planned PK, immunogenicity, and safety analyses  ................................ .........................  38 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 10 of 66  9.3.1  Pharmacokinetic analyses  ................................ ................................ ....................  38 
9.3.2  Immunogenicity analyses  ................................ ................................ ....................  39 
9.3.3  Safety analyses  ................................ ................................ ................................ ..... 39 
9.3.3.1  Adverse events  ................................ ................................ ..........................  39 
9.3.3.2  Vital signs  ................................ ................................ ................................ .. 39 
9.3.3.3  Physical examinations  ................................ ................................ ...............  39 
9.3.3.4  Pregnancy outcome  ................................ ................................ ...................  39 
9.4 Planned efficacy/outcome analyses  ................................ ................................ .................  39 
9.5 Handling of protocol deviations  ................................ ................................ .......................  39 
9.6 Handling of dropouts or missing data  ................................ ................................ ..............  39 
9.7 Planned interim analysis and data monitoring  ................................ ................................ . 40 
9.8 Determination of sample size  ................................ ................................ ...........................  40 
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  CONSIDERATIONS ... 40 
10.1  Appendix 1: Regulatory, ethical, and study oversight considerations  .............................  40 
10.1.1  Regulatory and ethical considerations  ................................ ................................ . 40 
10.1.2  Financial disclosure  ................................ ................................ .............................  41 
10.1.3  Informed consent process  ................................ ................................ ....................  41 
10.1.4  Data protection  ................................ ................................ ................................ ..... 41 
10.1.5  Committees structure  ................................ ................................ ...........................  42 
10.1.6  Data quality assurance  ................................ ................................ .........................  42 
10.1.6.1  Electronic Case Report Form completion  ................................ .................  42 
10.1.6.2  Apps  ................................ ................................ ................................ ...........  43 
10.1.7  Source documents  ................................ ................................ ................................  43 
10.1.8  Study and site closure  ................................ ................................ ..........................  43 
10.1.9  Publication policy  ................................ ................................ ................................  44 
10.2  Appendix 2: Clinical laboratory tests  ................................ ................................ ..............  45 
10.3  Appendix 3: Adverse events – Definitions and procedures for recording, evaluating, 
follow -up, and reporting  ................................ ................................ ................................ .. 46 
10.4  Appendix 4: Contraceptive guidance and collection of pregnancy information  .............  51 
Definitions   ................................ ................................ ................................ .....................  51 
10.5  Appendix 5: Genetics  ................................ ................................ ................................ ....... 52 
10.6  Appendix 6: Liver safety – Suggested actions and follow -up assessments  .....................  53 
10.7  Appendix 7: Medical device incidents – Definition and procedures for recording, 
evaluating, follow -up, and reporting  ................................ ................................ ................  54 
10.8  Appendix 8: Rapid alert procedures  ................................ ................................ ................  55 
10.9  Appendix 9: Country -specific requirements  ................................ ................................ .... 56 
10.10  Appendix 10: Abbreviations and trademarks  ................................ ........................  57 
10.11  Appendix 11: Protocol amendment history  ................................ ...........................  59 
11 REFERENCES  ................................ ................................ ................................ ................  65 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 11 of 66  SPONSOR DECLARATION  ................................ ................................ ................................ .. 66 
 
LIST OF TABLES  
Table  1‒1:  Schedule of Activities  ................................ ................................ ......................  17 
Table  8‒1:  Anticipated SAEs  ................................ ................................ .............................  35 
 
LIST OF FIGURES  
Figure  1‒1:  Study Diagram  ................................ ................................ ................................ . 15 
 
 
  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 12 of 66  1 PROTOCOL SUMMARY  
1.1 Synopsis  
Protocol title: A postmarketing, multicenter, longitudinal, prospective, pharmacokinetic, 
Phase  1B study in pregnant women with chronic inflammatory diseases treated with Cimzia® 
(certolizumab pegol).  
Short title: A postmarketing, multicenter, pharmacokinetic study in pregnant women with 
chronic inflammatory diseases treated with certolizumab pegol.  
Rationale:  
Certolizumab pegol (CZP) is approved in ad ults for the treatment of chronic inflammatory 
diseases (such as rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and 
axial spondyloarthritis [including ankylosing spondylitis and non -radiographic axial 
spondyloarthritis]) in m ultiple countries worldwide.  
Depending on the severity and condition, active disease can impact the outcome for the mother 
and infant and may necessitate therapy, even during pregnancy. For women who continue CZP 
therapy during pregnancy, there is no robus t evidence available regarding the impact of 
pregnancy on pharmacokinetics (PK) during treatment with CZP. In order to ensure that women 
who require CZP treatment during pregnancy are able to achieve therapeutic steady state levels 
of CZP, it is valuable t o conduct studies evaluating whether the physiologic changes underlying 
pregnancy impact the PK profile of CZP during pregnancy.  
The objective of this longitudinal, prospective, open -label PK study is to assess any changes in 
CZP ( the study medication in this protocol) plasma concentrations over the course of pregnancy, 
relative to the postpartum period.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 13 of 66  Objectives and endpoints:  
Objectives  Endpoints  
Primary  
• To assess systemic CZP exposure across 
the course of pregnancy in study 
participants with chronic inflammatory 
diseases  • Predose and postdose plasma CZP 
concentrations in women during 
pregnancy, relative to postpartum  
Secondary  
• To assess the formation of anti -CZP 
antibodies across the course of pregnancy  • Plasma levels of anti-CZP antibodies 
throughout the study period  
• To assess the safety of CZP in study 
participants with chronic inflammatory 
diseases across the course of pregnancy  • Adverse events from time of informed 
consent through SFU  
• Pregnancy outcome  
Other  
• To asses s changes in BMI, CRP and 
albumin across the course of pregnancy  • BMI  
• CRP levels  
• Albumin levels  
BMI=body mass index; CRP=C -reactive protein; CZP=certolizumab pegol; SFU=Safety Follow -Up 
Overall design:  
This is a Phase 1B, multicenter, longitudinal, interventional, prospective, PK, open -label study 
evaluating the impact of pregnancy on the PK of CZP. The study will recruit women who are 
already on prescribed commercial CZP with both a dosing regimen selec ted with guidance from 
the participant’s treating physician and an indication approved for use in their country, and who 
become pregnant and continue treatment with CZP. A postpartum predose blood sample will be 
taken 12  weeks (±1 week) after delivery, onc e the mother is considered to have returned to a 
pre-pregnancy physiological state, will serve as a within -participant reference sample. If 
possible, a postdose sample will be taken 1  week (±1 day) after the 12 -week postpartum dose.  
This study is considere d interventional due to the collection of blood samples from the women, 
which is not part of routine clinical practice. However, it is noninterventional regarding 
treatment with CZP and will only include pregnant women who decided with their treating 
physi cian to continue treatment with CZP prior to being recruited for and enrolled in the study.  
The study consists of a Screening Period, Sampling Period (consisting of a Pregnancy Period and 
Postpartum Period), and a Safety Follow -up (SFU) contact, as shown i n Figure  1‒1 and 
described below.  
The full Schedule of Activities is provided in  Table  1‒1. 
• Screenin g Period: Women of childbearing potential already on commercial CZP can register 
to indicate interest in the current study. After confirmation of pregnancy, the women will 
consent to participate in the study and will be eligible to enroll once CZP levels h ave reached 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 14 of 66  steady state. Confirmation of steady state is based on participant records and/or reports from 
the prescribing physician indicating that the participant has taken CZP for at least 12 weeks 
at the same dosing regimen prior to the Enrollment Visi t, which must take place at 
≤10 weeks gestational age.  
• Sampling Period:  
− Pregnancy Period: PK samples will be collected prior to the subsequent dose (predose) 
every 4 weeks (Q4W) starting with the first dose after enrollment. Further, postdose 
(7 ± 1 day af ter dose administration) PK samples will be collected every 8  weeks (Q8W) 
throughout the pregnancy. It is expected that there will be approximately 6 predose and 
3 postdose PK  samples collected per study participant (if there are no discontinuations) 
over the pregnancy.  
− Postpartum Period: A predose sample 12 weeks (±1 week) postpartum will be collected 
during the Postpartum Period. If possible, 1 additional postdose sample 1 week (±1 day) 
after the 12 weeks postpartum dose will also be collected.  
• Safety Fol low-up contact: All study participants will be contacted via telephone for a 
SFU 5 weeks (±5 days) after final study visit.  
If any participant withdraws early, she will complete the SFU contact.  
The end of the study is defined as the date of the SFU/last c ontact of the last participant in the 
study.  
Number of participants:  
Approximately 25 to 30 participants are planned to be screened to achieve approximately 
20 enrolled study participants (ie,  study participants who have provided the first blood sample). 
Enrollment will occur until a minimum of 10 study participants have longitudinal data (defined 
as at least 4 quantifiable predose and 2 quantifiable postdose PK samples during pregnancy and 
at least 1 quantifiable postpartum sample) over the study period.  
Treatment groups and duration:  
This study will include pregnant women who have decided to continue treatment with 
commercial CZP in accordance with their treating physician prior to participating in the study. 
Study participants will be responsible for obt aining and administering commercially available 
CZP under the care of their physician and according to the locally approved product label.  
The total study duration for a study participant will be a maximum of 53 weeks (40 weeks 
gestation period and up to 13 weeks (±3 days) postpartum).  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   30 Aug 2022  
Clinical Study Prot ocol Certolizumab pegol  UP0085  
   
Confidential  Page 15 of 66 1.2 Schema  
A schematic of the study design is provided in  Figure  1‒1. 
Figure  1‒1: Study Diagram  
 
CZP=certolizumab pegol; PK=pharmacokinetics; Q2W=every 2 weeks; Q4W=every 4 weeks  
a CZP dosing for at least 12  weeks before enrollme nt 
b First CZP dose post -enrollment  
c Timing and the number of visits across the pregnancy will vary for individual study participants  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
   
Confidential  Page 16 of 66 1.3 Schedule of Activities  
The Schedule of Activities is provided in  Table  1‒1. 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
   
Confidential  Page 17 of 66 Table  1‒1: Schedule of Activities  
Procedurea Screening  Sampling Period  SFU/EWD 
(via 
telephone)c Pregnancy Period  Postpartum Periodb 
V1d V2 
(Enrollment)  Predosee 
(Q4W)  Postdosef 
(Q8W)  V5 
Predosee  
 V6 
Postdosef 
(optional)  V7g 
 
Informed consent  X       
Demographics and baseline 
characteristics h X       
Verification of 
inclusion/exclusion criteria  X X      
Significant 
medical/procedures history 
and concomitant diseases  X       
Concomitant medication and 
procedures review  X X X X X X X 
Adverse event reviewi X X X X X X X 
Recording of commercial 
CZP treatmentj X X X X X X X 
Physical examinationk X       
Vital signsl X       
Tobacco and alcohol 
consumption, and drug abuse  X       
TB questionnairem X       
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
   
Confidential  Page 18 of 66 Table  1‒1: Schedule of Activities  
Procedurea Screening  Sampling Period  SFU/EWD 
(via 
telephone)c Pregnancy Period  Postpartum Periodb 
V1d V2 
(Enrollment)  Predosee 
(Q4W)  Postdosef 
(Q8W)  V5 
Predosee  
 V6 
Postdosef 
(optional)  V7g 
 
TB test (if not within 
6 months)n,o X       
Blood sampling for plasma 
CZP PK levels   X X X X X  
Blood sampling for plasma 
anti-CZP antibodies   X X  X   
Study participant diary 
completion/review  X X X X X X  
Blood sampling for CRP and 
albumin   X X  X   
Weight  (for BMI 
calculation)   X X  X   
Pregnancy outcome      X   
SFU contact        X 
BCG=Bacillus Calmette –Guérin; BMI=body mass index; CRP=c -reactive protein; CZP=certolizumab pegol; EWD=Early Withdrawal/Discontinuation; 
ICF=informed consent form; PK=pharmacokinetic; Q4W=every 4 weeks; Q8W=every 8 weeks; SFU=Safety Follow -up; TB=tuberculosis; V=Visit  
a It is expected that PK samples may not be obtainable in every case. Therefore, mis sing samples should not be considered major protocol deviations.  
b Postpartum samples will be collected up to 13 weeks (±3 days)  postpartum.  
c The SFU telephone contact will take place 5 weeks (±5 days) after the last study visit for all study participants . 
d Visit 1 may take place at an on -site or off -site location, conducted by the investigator or appropriate designee (eg, study participant’s local healthcare 
provider).  
e Predose samples will be collected within 4 hours prior to dosing.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
   
Confidential  Page 19 of 66 Table  1‒1: Schedule of Activities  
Procedurea Screening  Sampling Period  SFU/EWD 
(via 
telephone)c Pregnancy Period  Postpartum Periodb 
V1d V2 
(Enrollment)  Predosee 
(Q4W)  Postdosef 
(Q8W)  V5 
Predosee  
 V6 
Postdosef 
(optional)  V7g 
 
f Postdose samples  will be collected 7 (±1) days after the dose has been administered.  
g The SFU will take place 5 weeks (±5 days) after the last study visit.  
h Demographic and baseline characteristics will include lifestyle, confirmation of pregnancy, height, weight and BM I. 
i Adverse events will be collected from the time of the signature on the ICF until the SFU contact.  
j The decision to treat with CZP will be made by the study participant in accordance with her treating physician prior to being rec ruited for the study. Study 
participants are responsible for obtaining their own supply of commercial CZP. Final dosing of CZP during the study will be r ecorded during the SFU.  
k Physical examinations may be performed by the study participant’s local healthcare provider, and a record of that examination is to be provided to the 
investigator as documentation.  
l Vital signs include pulse rate, respiratory rate, systolic and diastolic blood pressure, and peripheral body temperature. Stu dy participants should maintain a 
sitting posi tion for ≥5 minutes before and during vital signs assessments.  
m Includes signs and symptoms of active TB and risk factors for exposure to TB and requires an assessment every 12 weeks. No ch est x -rays or follow -up 
testing will be performed, as this study w ill comprise study participants who have a low risk for TB.  
n Tuberculosis test results that have been obtained within the previous 6 months prior to Screening with negative results are a cceptable. Study participants 
with documented BCG vaccination and lo w risk of TB do not need to have TB test performed at Screening.  
o A TB test will only be offered within the study or at study exit if it has been 52 weeks since the last negative test and a t est is clinically indicated.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 20 of 66 2 INTRODUCTION  
Certolizumab pegol has been approved for use in patients with rheumatoid arthritis, psoriatic 
arthritis, plaque psoriasis, Crohn’s disease, and axial spondyloarthritis (including ankylosing 
spondylitis and non -radiographic axial spondyloarthriti s) in multiple countries worldwide. 
Limited data exist on the use of CZP in pregnant women, and are not sufficient to indicate how 
the physiologic changes of pregnancy can alter the PK of CZP in pregnant women.  
2.1 Study rationale  
Certolizumab pegol is an engi neered, humanized, antigen -binding antibody fragment (Fab), with 
specificity for human tumor necrosis factor α, that is conjugated to polyethylene glycol and is 
approved in adults for the treatment of the aforementioned chronic inflammatory diseases in 
multiple countries worldwide.  
Depending on the severity and condition, active disease can impact the outcome for the mother 
and infant and may necessitate therapy, even during pregnancy . For women who continue CZP 
therapy during pregnancy, there is no robust evidence available regarding the impact of 
pregnancy on PK during treatment with CZP . In order to ensure that women who require CZP 
treatment during pregnancy are able to achieve therapeutic steady state levels of CZP, it is 
valuable to conduct studies eva luating whether the physiologic changes underlying pregnancy 
impact exposure to CZP during pregnancy. As such, this study will evaluate the PK of CZP 
during pregnancy.  
For further information regarding the study rationale see Section  4.2. 
2.2 Background  
Autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, plaque psoriasis , Crohn’s 
disease, and axial spondyloarthritis (including ankylosing spondylitis and non -radiographic axial 
spondyloarthritis) affect women of childbearing age. While disease activity may spontaneously 
improve during pregnancy, approximately 50% of women with rheumatic chronic inflammatory 
diseases nee d effective therapeutic intervention and are faced with difficult questions regarding 
the impact of active disease on the fetus and the safety of different therapies during pregnancy. 
Depending on the severity and condition, active disease can impact the o utcome for the mother 
and infant and may necessitate therapy, even during pregnancy. Published data suggest that the 
risk of adverse pregnancy outcomes in women with rheumatoid arthritis or Crohn’s disease is 
correlated with maternal disease activity and t hat active disease increases the risk of adverse 
pregnancy outcomes, including fetal loss, preterm delivery (before 37 weeks of gestation), low 
birth weight (<2500g) and small for gestational age birth. Consequently, physicians and their 
patients may decid e to continue to treat disease during pregnancy.  
As described by Mariette (2018), physiologic changes during pregnancy may substantially alter 
drug PK; however, there are very limited data available on the impact of pregnancy on CZP PK.  
It is valuable to p rovide data about CZP levels throughout pregnancy to help women and their 
physicians make informed decisions about the dose of CZP to use during pregnancy, if a decision 
to continue treatment with CZP has been made.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 21 of 66 2.3 Benefit/risk assessment  
A clinical postm arketing prospective study (UP0017) evaluating placental transfer of CZP by 
measuring the plasma concentration of CZP from blood samples taken from infant, mother, and 
umbilical cord at delivery/birth indicated that there was minimal placental transfer of CZP from 
mother to infant. The mothers had similar CZP plasma concentrations at delivery to those of 
nonpregnant women receiving a maintenance dose regimen, and there were no detectable 
measurements of anti -CZP antibodies using the assay available at the t ime of the study in either 
the mothers or the infants, nor were there new safety signals.  
UP0085 will only include pregnant women who decided to continue treatment with CZP in 
accordance with their treating physician prior to participating in the study. Th erefore, the 
additional risks to participants due to participation in the study will be nominal (eg, possible 
complications associated with collection of blood samples and collection of participant data). 
Study participants will not directly benefit from p articipation in the study; however, the data 
obtained will enable physicians, pregnant women, and women of childbearing age to be better 
informed regarding PK of CZP when used during pregnancy.  
For more detailed information (eg,  PK and safety), as well as information about the known and 
expected benefits and risks and expected adverse events (AEs) of CZP, see the current 
Investigator’s Brochure (IB).  
As per routine UCB pharmacovigilance activity, all women who are administered CZP prior to 
the estimated dat e of conception or at any time during their pregnancy will be asked to complete 
the UCB Pregnancy Report and Outcome Form together with their treating physician 
(see Section  10.4). This process will apply also to participants of this study and enable UCB to 
collect information on the pregnancy and its outcome.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 22 of 66 3 OBJECTIVES AND ENDPO INTS  
Objectives  Endpoints  
Primary  
• To assess systemic CZP exposure across 
the course of pregnancy in study 
participants with chronic inflammatory 
diseases  • Predose and postdose plasma CZP 
concentrations in women during 
pregnancy, relative to postpartum  
Secondary  
• To assess the formation of anti -CZP 
antibodies across the c ourse of pregnancy  • Plasma levels of anti -CZP antibodies 
throughout the study period  
• To assess the safety of CZP in study 
participants with chronic inflammatory 
diseases across the course of pregnancy  • Adverse events from time of informed 
consent through SFU 
• Pregnancy outcome  
Other  
• To assess changes in BMI, CRP and 
albumin across the course of pregnancy  • BMI  
• CRP levels  
• Albumin levels  
BMI=body mass index; CRP=C -reactive protein; CZP=certolizumab pegol; SFU=Safety Follow -Up 
4 STUDY DESIGN  
4.1 Overall design  
This is a multicenter, longitudinal, interventional, prospective, PK, open -label study evaluating 
the impact of pregnancy on the PK of CZP. This is a Phase 1B (clinical pharmacology) 
exploratory study. The study will recruit women who are already on prescr ibed commercial CZP 
with a dosing regimen selected with guidance from the participant’s treating physician and for a 
given indication (approved for use in their country) and who become pregnant and continue 
treatment with CZP. A postpartum predose sample will be taken 12 weeks (±1 week) after 
delivery, once the mother is considered to have returned to a pre -pregnancy physiological state, 
will serve as a within -participant reference sample. If possible, a postdose sample will be taken 
1 week (±1 day) after t he 12 -week postpartum dose.  
The study is interventional due to the additional collection of blood samples from women. 
However, all other study assessments are part of routine clinical practice (with the exception of 
the diary), and the decision to continue /discontinue CZP therapy during pregnancy will be made 
between the participant and her treating physician, taking into account the potential risks to the 
mother and the benefits of CZP therapy, and according to the applicable local label.  
Study participan ts should have taken CZP for at least 12  weeks at their dosing regimen prior to 
enrollment and before the end of 10 weeks gestational age (see Inclusion Criterion [IC] 3). The 
study will enroll participants based on a minimum of 10 study participants providing longitudinal 
data (defined as at least 4 quantifiable predose and 2 quantifiable postdose PK samples during 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 23 of 66 pregnancy and at least 1 quantifiable  postpartum sample) over the study period. Study enrollment 
may be stopped after the minimum number of participants is reached, or the study may continue 
to enroll beyond the minimum number of participants if the cumulative study PK data are not 
deemed suf ficient to meet the primary objective.  Study participants will be provided with a diary 
to record all CZP dosing dates and times over the study period. Pharmacokinetic samples (for the 
determination of CZP concentration and anti -CZP antibody titers) will b e collected as detailed 
above, and samples will be collected for assessment of C -reactive protein (CRP) and albumin 
(covariates of the PK parameters). Overall safety and welfare of the mother and fetus are of 
paramount importance while performing any study -related activity.  
If a study participant has at least 1 PK sample obtained during pregnancy and then CZP dosing is 
interrupted and restarted, or dosing is modified during pregnancy, the study participant will 
continue to be followed and all samples will b e obtained per protocol guidelines (including 
postpartum samples).  
If a study participant has multiple PK samples obtained during pregnancy and discontinues CZP 
during pregnancy (with the intention to restart CZP after delivery), a PK predose sample will b e 
obtained at 12 weeks (±1 week) postpartum with a potential postdose sample 1  week (±1 day) 
after the predose postpartum sample. If the study participant does not take CZP for at least 
12 weeks and provides a PK sample within this window, the study partic ipant will be 
discontinued from the study.  
The informed consent form (ICF) for this study may be available electronically and used by 
prospective study participants at a study center or a remote location. If a study participant 
consents to participate, she  will enter the Screening Period and all elements of eligibility will be 
confirmed prior to entering the Sampling Period. It is anticipated that the sampling visits will be 
completed in the study participant’s home setting or at a designated convenient loc ation in the 
presence of a qualified remote healthcare nurse. To facilitate these visits, the study participant 
should have access to a telephone. In most cases, remote healthcare nurses performing a visit to a 
study participant may complete study data for ms that can be entered into the database by the 
contract research organization (CRO) or site staff. In other cases, study participants may visit a 
clinic, study site, or other health care provider’s office for assessments or to provide blood 
samples.  
Labor atory kits will be provided to the health care providers, remote healthcare nurses, and the 
study participants (as back up) for collection of CZP plasma levels, anti -CZP antibody 
assessments, CRP and albumin during collection of the final PK  sample, in add ition to a safety 
evaluation. Albumin was previously found to be a significant covariate in CZP population PK 
analyses, and CRP is a PK covariate and marker of inflammatory state. All samples will be 
initially delivered to a central laboratory. Pharmacokin etic samples will then be periodically 
shipped to a bioanalytical laboratory for PK and immunogenicity assessments. Samples will be 
collected for analysis of PK, immunogenicity, CRP, and albumin. At the Screening Visit, which 
may be at an on -site or off -site location and may be conducted by the investigator or appropriate 
designee (eg, study participant’s local healthcare provider), a physical examination will be 
performed, and vital signs will be measured. Additionally, tuberculosis (TB) testing will be 
performed if the study participant has not been tested within 6 months prior to Screening and has 
no associated clinical evidence of an active TB infection. Procedures and documentation will 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 24 of 66 comply with local Institutional Review Board (IRB)/ Independent Eth ics Committee (IEC) 
requirements.  
4.2 Scientific rationale for study design  
Clinical studies typically exclude pregnant women and withdraw study participants once they 
become pregnant. This has created a lack of data regarding drug exposure that leaves both 
pregnant women and treating physicians without objective scientific evidence regarding dosing 
of CZP during pregnancy. Additionally, depending on the severity and condition, active disease 
can impact the outcome for the mother and infant and may necessitat e therapy, even during 
pregnancy . For women who continue CZP therapy during pregnancy, there is no robust evidence 
available regarding the impact of pregnancy on PK during treatment with CZP . In order to ensure 
that women who require CZP treatment during p regnancy are able to achieve therapeutic steady 
state levels of CZP, it is valuable to conduct studies evaluating whether the physiologic changes 
underlying pregnancy impact exposure to CZP during pregnancy. This study (UP0085) will 
generate further data r egarding steady state dosing of CZP during pregnancy, which can help to 
provide guidance on PK variability and the impact of pregnancy on CZP plasma levels.  
The objective of this longitudinal, prospective, open label PK study is to assess any changes in 
CZP plasma concentrations that may result from physiological changes that occur during 
pregnancy. Women who take CZP for approved indications and maintenance dosing regimens 
(200mg every 2 weeks [Q2W] or 2 x 200mg Q4W or 400mg Q2W) and who continue with CZP 
treatment after they have become pregnant will be eligible to be considered for enrollment into 
this study, which will generate important information on CZP exposure during pregnancy. To 
measure CZP plasma concentration at steady state during pregnancy and  after delivery, blood 
samples will be collected predose Q4W, postdose Q8W during the pregnancy, and 1 predose 
sample 12  weeks (±1 week) postpartum (with potential postdose sample 1  week [±1  day] after 
the postpartum sample) . Each study participant will se rve as her own control.  
4.3 Justification for dose  
The study will recruit pregnant women who are prescribed commercial CZP for an approved 
indication in the country where the study will be conducted. No dose adjustments or any other 
changes to treatment will b e mandated by the study protocol (see Section  6.6). The commercially 
approved dosing regimens (200mg Q2W or 400mg Q4W or 400mg Q2W) will be permitted  
following the guidance of each study participant’s physician. After entry into the study, the study 
participant’s physician may modify the dosing regimen as necessary. In such cases, 
non-approved CZP dosing regimens will also be allowed, at the discretion  of the study 
participant’s physician and in a manner independent of this study, as long as the regimen does 
not exceed 400mg Q2W and the dose is recorded in the diary.  
4.4 End of study definition  
A participant is considered to have completed the study if she has completed all phases of the 
study per protocol including the final study contact (SFU).  
The end of the study is defined as the date of the SFU/last contact of the last participant in the 
study.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 25 of 66 5 STUDY POPULATION  
Prospective approval of protocol deviatio ns to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1 Inclusion criteria  
To be eligible to participate/enroll in this study, all of the following criteria must be met at the 
Screening Visit (Visit 1). Eligibility must also be confirmed at Enrollment Visit (Visit 2), ie, just 
prior to blood sampling for PK. If a participant does not initially meet the enrollment criteria, she 
may be rescreened; however, a study participant may not be enrolled for consecu tive 
pregnancies.  
Participants are eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Participant must be ≥18 years of age at the time of signing the ICF.  
Type of participant and disease characteristics  
2. Participant must be considered reliable and capable of adhering to the protocol and visit 
schedule according to the judgment of the investigator.  
3. Participant is pregnant and ≤10 weeks gestation at the time of enrollment.  
4. Participant must have been on stabl e, maintenance dose CZP treatment for at least 12 weeks 
independent of and prior to being enrolled in this study, for an approved indication in 
accordance with her treating physician.  
5. Participant expects to continue CZP therapy throughout pregnancy and for  at least 12 weeks 
postpartum.  
6. Participant has  a negative interferon gamma release assay (IGRA) or tuberculin skin test 
(TST) within the prior 6 months, and there has been no change in the study participant’s 
clinical status, or social, family, or travel h istory. Participants with documented Bacillus 
Calmette –Guérin (BCG) vaccine and at low risk for TB may enroll without having a TB test 
performed.  
Sex 
7. Participants who are  female.  
Informed consent  
8. Participant is capable of giving signed informed consent as described in Section  10.1 
(Appendix 1)  which includes compliance with the requirements and restrictions listed in the 
ICF and in this protocol.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 26 of 66 5.2 Exclusion criteria  
Study participants are excluded from the study if any of the following criteria are met at the 
Screening Visit (Visit 1) or Enrollment Visit (Visit  2): 
Medical conditions  
1. Participant has any medical or psychiatric condition that, in the opinion of the investigator, 
could jeopardize or would compromise the study participant’s ability to participate in this 
study.  
2. Participant has a recent history of alcohol or drug abuse in the investigator’s medical 
judgment.  
3. Participant has any evidence o r medical history of an obstetrical or psychiatric condition, or 
she or her fetus has any medical condition or history (eg, primary or secondary 
antiphospholipid syndrome or hypercoagulable state) that, in the opinion of the investigator, 
could jeopardize or would compromise the study participant’s ability to participate in this 
study or the outcome of the pregnancy.  
4. Participant has any evidence of clinically significant anemia in the opinion of the 
investigator.  
5. Participant has had significant documented m orbidity during the past 12 weeks . 
6. Participant is not permitted to enroll into the study if she meets any of the following TB 
exclusion criteria:  
− Known active TB disease  
− History of active TB involving any organ system  
− Latent TB infection  
− High risk of acqui ring TB infection  
− Current nontuberculous mycobacterial (NTM) infection or history of NTM infection 
(unless proven to be fully recovered)  
7. Significant allergies to humanized monoclonal antibodies.  
8. Clinically significant multiple or severe drug allergies, or severe post -treatment 
hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear 
immunoglobulin A dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).  
9. Current or chronic history of clinically significant li ver disease, or known hepatic or biliary 
abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).  
Prior/concomitant therapy  
10. Study participant is taking a prohibited medication or has taken a prohibited medication as 
defined in S ection  6.5.2 . 
11. Live vaccine(s) within 1 month prior to Screening, or plans to receive such vaccines during 
the study.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 27 of 66 Prior/concurrent clinical study ex perience  
12. Participant has been dosed with an investigational medicinal product (IMP), blinded IMP, or 
has received an investigational medical device or procedure within the previous 120 days or 
5 half-lives (whichever is longer) prior to Screening or is currently participating in another 
study of an IMP, blinded IMP, or will receive an investigational medical device or procedure 
(excluding noninterventional or registry studies).  
Diagnostic assessments  
13. Study participant has any clinically significant pregn ancy -related clinical or test abnormality, 
as judged by the investigator.  
14. Study participant had a positive or indeterminate IGRA or TST test at Screening. In case of 
indeterminate result, a retest is allowed if time permits; 2 results of indeterminate requ ire 
exclusion of the study participant.  
15. Study participant has a history of human immunodeficiency virus, Hepatitis B surface 
antigen (HBsAg), or Hepatitis C antibody prior to starting the study.  
5.3 Lifestyle restrictions  
5.3.1  Meals and dietary restrictions  
No meal  or dietary restrictions are required during this study.  
5.3.2  Caffeine, alcohol, and tobacco  
No caffeine, alcohol, and tobacco restrictions are required during this study; any restrictions (for 
the purposes of routine clinical management) are left to the judgme nt of the investigator.  
5.3.3  Activity  
No activity restrictions are required during this study.  
5.4 Screen failures  
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently entered in the study. A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participants to meet the Consolidated Standards of 
Reporting Trials publishing requirements and to respond to queries from regulatory authorities. 
Minimal infor mation includes demography, screen failure details, eligibility criteria, and any 
serious adverse event (SAE).  
Individuals who do not meet the criteria for participation in this study (screen failures) may be 
rescreened ; however, a study participant may no t be enrolled for consecutive pregnancies . 
Rescreened participants should be assigned the same participant number as for the initial 
Screening.  
6 STUDY TREATMENT  
Study treatment is defined as an y investigational treatment(s), marketed product(s), placebo , or 
medical device (s) intended to be administered to a study participant according to the study 
protocol.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 28 of 66 6.1 Treatment administered  
This study will only include pregnant women who have decided to continue treatment with CZP 
in accordance with their treating phys ician prior to participating in the study. The CZP is not 
provided by the Sponsor. Study participants will be responsible for obtaining and administering 
commercially available CZP under the care of their physician.  
The commercially approved dosing regimen s (200mg Q2W or 400mg Q4W or 400mg Q2W) 
will be permitted following the guidance of each study participant’s physician.  
After entry into the study, the study participant’s physician may modify the dosing regimen as 
necessary. In such cases, non -approved CZP dosing regimens will also be allowed, at the 
discretion of the study participant’s physician and in a manner independent of this study, as long 
as the regimen does not exceed 400mg Q2W and the dose is recorded in the diary. Study 
participants will receive CZP in accordance with their treating physician until at least 12 weeks 
(±1 week) after delivery.  
6.2 Preparation, handling, storage, and accountability requirements  
Study participants will be responsible for obtaining and administering commercial ly available 
CZP under the care of their physician.  
Commercial CZP can be self -administered by subcutaneous injection using a prefilled syringe or 
prepared and administered by a health care professional if lyophilized powder is used.  
6.3 Measures to minimize b ias: Randomization and blinding  
All study participants will receive CZP under the care of their physician; thus there is no 
opportunity for bias. Based on this study design, randomization and blinding are not possible and 
are therefore not applicable to th is study.  
6.4 Treatment compliance  
Study participants will be provided with a diary to record all CZP dosing dates and times over 
the study period.  
6.5 Concomitant medication(s)/treatment(s)  
Unless otherwise prohibited per protocol exclusion criteria, study participants are permitted to 
continue on their prescribed medical therapy for the disease in accordance with the instructions 
of their treating physician.  
Any treatment other than commercial CZP (CZP dosing dates and times will be collected 
separately in a diary), including over -the-counter products and supplements, must be recorded in 
the study participant’s notes (source documentation) and provided on the electronic Case Report 
Form (eCRF). This record should include the name of the drug, the dose, the r oute, and date(s) of 
administration, and the indication for use.  
For the purposes of this study:  
• Past medications are those that are ongoing at the time of first day of the last menstrual 
period and those that started after the first day of the last menstr ual period that stopped prior 
to entering the Screening Period.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 29 of 66 • Prior medications are those that are ongoing at the time of first day of the last menstrual 
period and those that started after the first day of the last menstrual period prior to entering 
the Screening Period.  
• Concomitant medications are medications with at least 1 day in common with the Screening 
or Sampling Periods.  
• Prior medications may include both past medications and concomitant medications.  
6.5.1  Permitted concomitant treatments (medications and therapies)  
All concomitant medications are permitted, except for those noted in Section  6.5.2 . 
6.5.2  Concomitant medications that lead to study withdraw al 
The study participant must not participate in any other interventional clinical study or receive 
any unauthorized medication throughout the study period. Non -Interventional study (NIS) 
participation is allowed.  
There are no specific prohibited concomita nt medications in this study, as it is not the intention 
to interfere with the physician’s decision on treatment.  However, there are certain exclusion 
criteria and withdrawal criteria associated with concomitant medication use to ensure robust and 
interpr etable data.  These criteria include:   
• Any medication taken 12  weeks prior to conception with strong positive evidence of a human 
fetal risk of teratogenicity during pregnancy.  
− The study participant must be withdrawn from the study if she takes any medica tion 
(during the pregnancy) with strong positive evidence of a human fetal risk or other 
adverse outcomes.  
• Any biological therapeutic agent, including anti -TNFs other than CZP.  
• Any biological disease modifying drug (other than CZP), whether licensed or unl icensed, for 
the study participant’s disease during the pregnancy.  
6.6 Dose modification  
The study will recruit pregnant women who are prescribed commercial CZP for an approved 
indication in the country where study will be conducted. No dose adjustments will b e mandated 
by the study protocol. However, in the best interest of the study participant, the treating 
physician can modify the dosing regimen in accordance with local medical practice in the 
management of her disease, or the study participant might modify  her dosing regimen herself and 
any changes in dosing should be recorded in the diary. In these cases, the study participant will 
still be followed per protocol since the resultant data will be informative with the data analytical 
methodologies to be emplo yed. 
As described in Section  6.1, after entry into the study, the study participant’s physician may 
modify the dosing regimen as necessary. In such cases, non -approved CZP dosing regimens will 
also be allowed, at the discretion of the study participant’s physician and in a manner 
independent of this study, as long as the regimen does not exceed 400mg Q2W and the dose is 
recorded in the diary.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 30 of 66 6.7 Treatment after the  end of the study  
Study participants may continue to be treated with commercially -available CZP in accordance 
with their treating physician following completion of the study.  
7 DISCONTINUATION OF S TUDY MEDICATION AND PARTICIPANT 
DISCONTINUATION/WITH DRAWAL  
7.1 Discontinuation of study medication  
Administration of CZP is not dictated by this protocol; therefore there are no protocol -defined 
reasons a participant should permanently discontinue CZP treatment.  
7.1.1  Temporary discontinuation  
If a study participant has at le ast 1 PK sample obtained during pregnancy and then CZP dosing is 
interrupted and restarted, or dosing is modified during pregnancy, the study participant will 
continue to be followed and all samples will be obtained per protocol guidelines (including 
postp artum samples).  
If a study participant has multiple PK samples obtained during pregnancy and discontinues CZP 
during pregnancy (with the intention to restart CZP after delivery), a PK predose sample will be 
obtained at 12 weeks (±1 week) postpartum with a potential postdose sample 1  week (±1 day) 
after the predose postpartum sample. If the study participant does not take CZP for at least 
12 weeks and provides a PK sample within this window, the study participant will be 
discontinued from the study.  
7.2 Particip ant discontinuation/withdrawal from the study  
Participants are free to withdraw from the study at any time, without prejudice to their continued 
care.  
A participant may withdraw from the study at any time at her own request, or may be withdrawn 
at any time  at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons.  
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a wit hdrawal of consent.  
If a participant withdraws from the study, she may request destruction of any samples taken and 
not tested, and the investigator must document this in the site study records.  
See the Schedule of Activities (Section  1.3) for data to be collected at the time of study 
discontinuation and follow -up and for any further evaluations that need to be completed.  
Participants should be withdr awn from the study if any of the following events occur:  
1. Participant develops an illness that would interfere with her continued participation.  
2. Participant is noncompliant with the study procedures or medications in the opinion of the 
investigator.  
3. Partici pant takes concomitant medications that lead to study withdrawal as defined in this 
protocol (Section  6.5.2 ). 
4. Participant withdraws her consent.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 31 of 66 5. The sponsor or a regulatory agency requests withdrawal of the participant.  
6. If the study participant has a spontaneous abortion, the study participant will be discontinued 
from the study and a postpartum sample will not be obtained.  
7. If the study participant ceases CZP during pregnancy, and upon restarting after delivery does 
not take CZP for at least 12 weeks and provides a PK sample within the window defined  in 
Section  7.1.1 , the study participant will be discontinued from the study.  
8. If the study participant is given a dose of CZP exceeding 400mg Q2W,  the study participant 
will be discontinued from the study.  
Study participants should consult with their treating physician to determine the best method of 
ceasing administration of CZP based on recommendations located on the manufacturer’s label.  
Investigator s should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a participant in advance.  
7.3 Lost to follow up  
A participant  will be considered lost to follow up if she repeatedly misses scheduled visits and is 
unable to be contacted by the investigator.  
The following actions must be taken if a participant misses a required study visit:  
• The investigator  must attempt to contact the participant and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the participant wishes to and/or should continue in 
the study.  
• Before a participant is deemed lost to follow up, the investigator or designee must make 
every effort to regain contact with the participant (at least 1 phone call and 1 written message 
to the participant), and document his/her effort (date and summary of the pho ne call and copy 
of the written message in the source documents), to complete the final evaluation . All results 
of these evaluations and observations, together with a narrative description of the reason(s) 
for removing the participant, must be recorded in the source documents. The eCRF must 
document the primary reason for withdrawal.  
Should the participant continue to be unreachable, she will be considered to have withdrawn 
from the study with a primary reason of lost to follow up documented in the eCRF.  
8 STUDY ASSESSMENTS AND PROCEDURES  
Study procedures and their timing are summarized in the Schedule of Activities 
(see Section  1.3). 
Protocol waivers or exemptions are not allowed.  
It will be the responsibility of the treating physician to determine if the participant should 
continue or discontinue treatment.  The sponsor  should be informed immediately regarding safety 
concerns upon occurrence or awareness to determine if the participant should continue or 
discontinue participation in the study.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 32 of 66 Adherence to the study design requirements, including those specified in the S chedule of 
Activities (see Section  1.3), is essential and required for study conduct.  
All Screening evaluations must be completed and reviewed to co nfirm that potential participants 
meet all eligibility criteria. The investigator will maintain a Screening log to record details of all 
participants screened and to confirm eligibility or record reasons for Screening failure, as 
applicable.  
Procedures con ducted as part of the participant’s routine clinical management (eg, blood count)  
and obtained before signing of the ICF may be utilized for Screening or baseline purposes 
provided the procedures met the protocol -specified criteria and were performed within the time 
frame defined in the Schedule of Activities (see Section  1.3). 
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the 
samples.  
Study participants will be provided with a diary to record all CZP dosing dates and times over 
the study period.  
8.1 Efficacy  assessments  
Not applicable.  
8.2 Safety assessments  
Planned time points for all safety assessments are provided in the Schedule of Activities 
(Section  1.3). 
8.2.1  Physical examination  
A physical examination will take place at Screening, as specified in Section  1.3, and may be 
performed by the study participant’s local healthcare provider, and a record of that examination 
provided to the investigator as documentation.  
A physical examination will include , at a minimum, assessments of the skin, lungs, 
cardiovascular system, abdomen (liver and spleen).  
Investigators should pay special attention to clinical signs related to previous serious illnesses.  
Clinically relevant findings or worsening of previous fin dings will be recorded as AEs.  
8.2.2  Vital signs  
Peripheral body temperature, pulse rate, respiratory rate, and systolic and diastolic blood 
pressure will be assessed.  
Blood pressure and pulse measurements will be assessed with the study participant in a sitting  
position with a completely automated device. Manual techniques will be used only if an 
automated device is not available.  
Blood pressure and pulse measurements should be preceded by at least 5 minutes of rest for the 
participant in a quiet setting without  distractions (eg, television and/or cell phones).  
Vital signs (to be taken before blood collection for laboratory tests) will consist of 1 pulse and 
3 blood pressure measurements (3 consecutive blood pressure readings will be recorded at 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 33 of 66 intervals of at least 1  minute). The average of the 3 blood pressure readings will be recorded on 
the eCRF.  
8.2.3  Electrocardiograms  
Electrocardiograms will not be recorded in this study.  
8.2.4  Clinical safety laboratory assessments  
No clinical safety laboratory assessments will be p erformed in this study.  
8.2.5  Pregnancy outcome  
Information regarding pregnancy outcome and maternal hospitalization/delivery will be 
collected. The investigator should update the Pregnancy Report and Outcome form, as necessary, 
and send it to the Sponsor.  
Addit ional information regarding collection of pregnancy -related data is located in Appendix  4 
(Section  10.4). 
8.3 Adverse events  
The definitions of an AE and  SAE can be found in Appendix 3 (Section  10.3). 
Adverse events will be reported by the participant (or, when appropriate, by a caregiver, 
surrogate, o r the participant's legally authorized representative).  
The investigator and any designees are responsible for detecting, documenting, and recording 
events that meet the definition of an AE or SAE and remain responsible for following up AEs 
that are seriou s, considered related to CZP or study procedures, or that caused the participant to 
discontinue the study (see Section  7). 
8.3.1  Time period and frequency  for collecting AE and SAE information  
All AEs and SAEs will be collected from the signing of the ICF  until the SFU visit  at the time 
points specified in the Schedule of Activities ( Section  1.3). 
In order to ensure complete safety data collection, all AEs occurring during the study (ie,  after 
the signing of the ICF), including any pretreatment and posttreatment periods required by t he 
protocol, must be reported in the eCRF. This includes all AEs not present prior to the initial visit 
and all AEs that recurred or worsened after the initial visit.  
All SAEs will be recorded and reported to the Sponsor  or designee within 24 hours, as ind icated 
in Appendix 3 ( Section  10.3). The investigator will submit any updated SAE data to the Sponsor 
within 24  hours of it being available.  
The invest igator is specifically requested to collect and report to UCB (or its representative) any 
SAEs (even if the investigator is certain that they are in no way associated with CZP), up to 
35 days (±5  days) after the final blood sample is obtained for each part icipant, and to also inform 
participants of the need to inform the investigator of any SAE within this period. Serious AEs 
that the investigator thinks may be associated with CZP must be reported to UCB, regardless of 
the time between the event and the end  of the study.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 34 of 66 The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 
(Section  10.3). 
8.3.2  Method of detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire abo ut 
AE occurrences.  
8.3.3  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. All SAEs, and nonserious AEs of special interest (as defined in 
Section  8.3.6 ), will be followed until resolution, stabilization, the investigator determines that it 
is no longer clinically significant, the event is otherwise explained, or the participant is lost to 
follow up (as defined in Section  7.3). Further information on follow -up procedures is given in 
Appendix 3 (Section  10.3). 
8.3.4  Regulatory reporting requirements for SAEs  
Prompt notification by the investigator to the Sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities towa rds the safety of participants and the safety of CZP 
under clinical investigation are met.  
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of CZP under clinical investigati on. The Sponsor will 
comply with country -specific regulatory requirements relating to safety reporting to the 
regulatory authority, IRB/IEC , and investigators.  
Investigator safety reports must be prepared for suspected unexpected serious adverse reactions 
according to local regulatory requirements and Sponsor policy and forwarded to investigators as 
necessary.  
An investigator who receives an investigator safety report describing a SAE or other specific 
safety information (eg, summary or listing of SAEs) fro m the Sponsor will review and then file it 
along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.  
8.3.5  Pregnancy  
Details of the pregnancies for all study participants will be collected from enrollment into the 
study and u p to the SFU. UCB standing guidance for collection of data pertaining to pregnancy 
and pregnancy outcomes will be used during this study for the collection of such data 
(Section  8.2.5 ). Information regarding collection of pregnancy -related data is located in 
Appendix 4 Section  10.4.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, and ectopic pregnancy) are considered SAEs.  
8.3.6  Adverse events of special interest  
An AE of  special interest is any AE that a regulatory authority has mandated to be reported on an 
expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 35 of 66 For CZP, the following events require immediate reporting (within 24 hours regardless of 
seriousness) to UCB:  
• Hy’s Law  
− Potential Hy’s Law, defined as ≥3x upper limit of normal (ULN) alanine 
aminotransferase or aspartate aminotransferase with coexisting ≥2xULN total bilirubin in 
the abs ence of ≥2xULN alkaline phosphatase , with no alternative explanation for the 
biochemical abnormality (ie, without waiting for any additional etiologic investigations 
to have been concluded). Follow -up information should then be reported if an alternative 
etiology is identified during investigation and monitoring of the participant.  
• Serious infections including opportunistic infections  
• Malignancies including lymphoma  
• Congestive heart failure  
• Demyelinating -like disorders  
• Aplastic anemia, pancytopenia, thrombo cytopenia, neutropenia, and leucopenia  
• Serious bleeding events  
• Lupus and lupus -like syndrome  
• Serious skin reactions (eg, Stevens Johnson Syndrome, toxic epidermal necrosis, and 
erythema multiforme).  
8.3.7  Disease -related events and/or disease -related outcomes no t 
qualifying as AEs or SAEs  
Anticipated SAEs are anticipated to occur in the population studied in this protocol at some 
frequency that is independent of drug exposure. A summary of anticipated SAEs is presented in 
Table  8‒1 (Appendix 3).  
This list does not change the investigator’s obligation to report all SAEs (including Anticipated 
SAEs) as detailed in Section  8.3.1  and Section  10.3 (Appendix 3).  
Table  8‒1: Anticipated SAEs  
Population  Anticipated SAE(s)  
Rheumatoid arthritis  Rheumatoid arthritis  
Crohn’s disease  Crohn’s disease  
Perianal abscess  
Abdominal pain  
Ankylosing spondylitis  Ankylosing spondylitis  
Psoriatic arthritis  Psoriatic arthritis  
Plaque psoriasis  Plaque psoriasis  
SAE=serious adverse event  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 36 of 66 8.4 Safety signal detection  
Selected data from this study will be reviewed periodically to detect as early as possible any 
safety concern(s) related to CZP so that investigators, clinical study participants, regulatory 
authorities, and IRBs/IECs will be informed appropriately and as early as possible.  
The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs and per form ongoing SAE reconciliations in collaboration with the Patient Safety 
representative.  
As appropriate for the stage of development and accumulated experience with CZP, medically 
qualified personnel at UCB may identify additional safety measures (eg,  AEs, vital signs) for 
which data will be periodically reviewed during the course of the study.  
8.5 Treatment of overdose  
Excessive dosing (beyond that prescribed per the local label) will be recorded by the study 
participant in the diary and also recorded in the eCRF.  The dosing documentation will be 
reviewed and verified by the investigator and/or home health nurse. Any SAE or nonserious AE 
associated with excessive dosing must be followed as any other SAE or nonserious AE. 
Overdose events are only considered AE s or SAEs if there are associated clinical signs and 
symptoms or if the act of taking the excess CZP itself is an AE or SAE (eg, suicide attempt).  
UCB  does not recommend specific treatment for an overdose . In the event of an overdose, the 
treating physicia n should:  
1. Contact the Medical Monitor immediately.  
2. Closely monitor the participant for any AE/SAE and laboratory abnormalities until 
commercial CZP can no longer be detected systemically (at least 70 days).  
3. Obtain a plasma sample for PK analysis within 70 days from the date of the last dose of 
commercial CZP if requested by the Medical Monitor (determined on a case -by-case basis).  
4. Document the quantity of the excess dose as well as the duration of the overdose in the 
eCRF.  
8.6 Pharmacokinetics  
Plasma and whole blood samples of approximately 5mL will be collected for measurement of 
plasma concentrations of CZP as specified in the Schedule of Activities (Section  1.3). Samples 
may be collected at additional time points during the study, if warranted and agreed upon 
between the investigator and the Sponsor. Instructions for the collection and handling of 
biological samples will be provided by the Sponsor. The a ctual date and time (24 -hour clock 
time) of each sample will be recorded.  
Samples will be used to evaluate the PK of CZP. Each plasma sample will be divided for PK and 
immunogenicity analyses. Samples collected for analyses of CZP plasma concentration may also 
be used to evaluate safety or efficacy aspects related to concerns arising during or after the study.  
8.7 Pharmacodynamics  
Pharmacodynamic parameters  are not evaluated in this study.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 37 of 66 8.8 Genetics  
Genetics are not evaluated in this study.  
8.9 Biomarkers  
Immunogenicity assessments will be the only biomarkers evaluated in this study. Additionally, 
serum CRP and albumin are being measured as these markers have previously been found to be 
influential determinants in the description of CZP population PK.  
8.9.1  Immun ogenicity assessments  
Antibodies to CZP will be evaluated in plasma samples collected from all participants according 
to the Schedule of Activities (Section  1.3). These samples will be tested by the Sponsor or 
Sponsor's designee.  
Plasma samples will be screened for antibodies binding to CZP and the titer of confirmed 
positive samples will be reported. Other analyses may be performed to further charact erize the 
immunogenicity of CZP.  
The detection and characterization of antibodies to CZP will be performed using a validated 
assay method by or under the supervision of the Sponsor. All samples collected for detection of 
antibodies to CZP will be used to a ssess the effect on CZP exposure.  
9 STATISTICAL CONSIDER ATIONS  
A description of statistical methods follows and will be described in more detail in the Statistical 
Analysis Plan (SAP).  
9.1 Definition of analysis sets  
There will be 4 analysis sets for the study; the All Study Participants Screened Set, the Enrolled 
Set (ES), the Safety Set (SS) and the Pharmacokinetic Per Protocol Set (PK -PPS).  
The All Study Participants Screened Set will consist of all study participants who have signed 
the ICF and will include all participants who pass screening as well as screen failures. This will 
be the largest analysis set.  
The Enrolled Set (ES) will include all study participants who are confirmed as having signed the 
ICF to participate in the study and have provided the f irst blood sample.  
The Safety Set (SS) will include all enrolled study participants who received at least 1 dose of 
CZP after Screening.  
The Pharmacokinetic Per -Protocol Set (PK -PPS) is a subset of the SS, consisting of those study 
participants who had no important protocol deviations affecting the CZP plasma concentration 
and for whom a sufficient number of samples are available.  
9.2 General statistical considerations  
All analyses will be performed using statistical analysis system (SAS®, SAS Institute, Cary, NC, 
USA) Version 9.4 or higher using validated program code according to relevant UCB standard 
operating procedures.  
In general, summary statistics (n [number of available measurements], arithmetic mean, standard 
deviation [SD], median, minimum, and maximu m) for quantitative variables and frequency 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 38 of 66 tables for qualitative data will be presented. The arithmetic mean and SD will be replaced by the 
geometric mean and coefficient of variation (CV), respectively, for quantitative PK data. Any 
further deviations f rom this general approach will be outlined in the SAP.  
Baseline characteristics will be summarized based on the ES. Adverse event data collected will 
be summarized based on the SS. For PK measurements, the data will be summarized based on 
the PK -PPS.  
For summaries of plasma concentration data, baseline will be defined as the predose 
measurement 12 weeks (±1 week) postpartum.  
9.3 Planned PK, immunogenicity, and safety analyses  
Details regarding study participant disposition and characteristics will be provi ded in the SAP.  
9.3.1  Pharmacokinetic analyses  
All PK analyses will be performed on the PK -PPS. The individual plasma concentrations of CZP 
will be summarized over the course of pregnancy by trimester and dosing time point (predose or 
postdose) using graphs and descriptive statistics (number of observations [n], geometric mean, 
lower and upper 95% confidence intervals [CI], geometric CV, arithmetic mean, SD, CV, 
median, minimum, and maximum values).  
For the calculation of descriptive statistics, a plasma concentr ation below the lower limit of 
quantification (LLOQ) will be substituted by LLOQ/2. The geometric and arithmetic means and 
associated SD, lower and upper limits of 95% CI, and CV will be calculated only if at least 
two-thirds of the individual data at a sp ecific sampling point are measured, are above or equal to 
LLOQ, and N≥4.  
The CZP plasma concentrations (primary variable) will be analyzed using a linear mixed effect 
model (disease phenotype, time point, trimester [trimester 1, 2, 3, or postpartum] and wh ether the 
sample was predose or postdose [binary indicator] may be used as fixed effects, and the random 
effect will be study participant). Mean differences with 95% CI of CZP plasma concentrations 
between samples taken during pregnancy and baseline (predo se measurement at 12  weeks 
(±1 week) postpartum and potential postdose sample 1  week [±1 day] after the predose 
postpartum sample ) will be estimated within this mixed effect model using contrasts. A forest 
plot of mean trough CZP plasma concentrations with  95% CI of each sampling time point during 
pregnancy and postpartum will be displayed. Data analysis may be conducted on 
log-transformed data (and back -transformed results displayed). Then, the change from baseline 
in CZP plasma concentrations across trime sters will be adjusted for the clinical covariates of 
albumin, body mass index (BMI), CRP (or any other relevant covariates) and disease phenotype 
using a multivariate linear mixed -effects model. The resulting coefficient b -estimate represents 
the change i n CZP plasma concentrations for a unit increase in that predictor.  
Pharmacokinetic data from this study will also be analyzed using population PK methodologies, 
which will enable derivation of (posthoc) PK parameters throughout the study periods, as well a s 
enable accounting for individual variations in dosing regimens and times.  
Any additional analyses may be defined in the SAP.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 39 of 66 9.3.2  Immunogenicity analyses  
Immunogenicity (anti -CZP antibody levels) will be assessed through summary tables, figures 
and listings o f individual results by study participant. All analyses will be performed using the 
SS, unless otherwise specified. For all tabulations, percentages will be calculated based on the 
number of study participants with nonmissing data. More details will be pro vided in the SAP.  
9.3.3  Safety analyses  
All safety analyses will be performed using the SS. All safety variables will be summarized by 
study part (each sampling point or postpartum).  
9.3.3.1  Adverse events  
All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA v24.1  
or higher ) and characterized as treatment -emergent according to the intake of CZP.  
The occurrence and incidence of treatment -emergent adverse events (TEAEs) will be 
summarized by MedDRA system organ class and preferred t erm. The occurrence and incidence 
of TEAEs will also be summarized by intensity and by relationship to CZP. Adverse events 
leading to discontinuation and SAEs will also be summarized.  
9.3.3.2  Vital signs  
Measured values of vital signs (blood pressure [systolic and  diastolic], respiratory rate, pulse 
rate, and peripheral body temperature) at Screening will be summarized descriptively.  
9.3.3.3  Physical examinations  
Physical examination abnormalities will be listed.  
9.3.3.4  Pregnancy outcome  
Pregnancy outcome by study participant wil l be included in a listing.  
9.4 Planned efficacy/outcome analyses  
Not applicable.  
9.5 Handling of protocol deviations  
No protocol deviation is permitted, either in retrospect or prospect.  
Important protocol deviations are deviations from the protocol which potenti ally could have a 
meaningful impact on study conduct or on the key safety or PK outcomes (if applicable) for an 
individual study participant. The criteria for identifying important protocol deviations will be 
defined within the important protocol deviation s document. Important protocol deviations will be 
reviewed as part of the ongoing data cleaning process and data evaluation. All important 
deviations will be identified and documented prior to database lock to confirm exclusion from 
analysis sets.  
9.6 Handling  of dropouts or missing data  
There will be no special procedures for handling missing data. All imputation of missing or 
partial dates for safety assessments, as well as handling values below the LLOQ in the PK data, 
will be detailed in the SAP.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 40 of 66 9.7 Planned in terim analysis and data monitoring  
Not applicable.  
9.8 Determination of sample size  
Because no formal hypothesis testing will be conducted, the sample size of 15 study participants 
is deemed sufficient for a small exploratory Phase 1B study. It is expected tha t up to 25 to 
30 women will need to be screened to ensure that approximately 20 study participants are 
enrolled, in order to allow for approximately 15 evaluable study participants. These 15 evaluable 
participants are expected to provide the minimum of 10 study participants providing longitudinal 
data as defined in Section  4.1. 
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  
10.1 Appendix 1: Regulatory, ethical, and study oversight 
considerations  
10.1.1  Regulatory and ethical considerations  
This study will be conducted under the auspices of an IRB/IEC, as defined in local regulations, 
International Council for Harmonisation  (ICH) -Good Clinical Practi ce (GCP), and in accordance 
with the ethical principles that have their origin in the Declaration of Helsinki.  
The investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies with 
the requirements of the current ICH -GCP version or applicable country -specific regulations will 
be responsible for the initial and continuing review and approval of the clinical study. Prior to 
initiation of the study, the investigator/UCB will forward copies of the protocol, ICF, IB, 
investigator’s curric ulum vitae (if applicable), advertisement (if applicable), and all other 
participant -related documents to be used for the study to the IRB/IEC for its review and 
approval.  
Before initiating a study, the investigator will have written and dated full approva l from the 
responsible IRB/IEC for the protocol.  
The investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to participants or others, and any protocol deviations, to 
eliminate immediate hazards to participants.  
The investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the participants. 
For minor changes to a previously approved proto col during the period covered by the original 
approval, it may be possible for the investigator to obtain an expedited review by the IRB/IEC as 
allowed.  
As part of the IRB/IEC requirements for continuing review of approved studies, the investigator 
will be  responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropriate to the degree of participant risk involved, but no less than 
once per year. The investigator should provide a final report to the  IRB/IEC following study 
completion.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 41 of 66 UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active investigators in accordance with applicable regulatory requirements. 
The appropriate IRB/IEC will also be informed by the investigator or the Sponsor, as specified 
by the applicable regulatory requirements in each concerned country. Where applicable, 
investigators are to provide the Sponsor (or its representative) with evidence of such IRB/IEC 
notifica tion. 
10.1.2  Financial disclosure  
Insurance coverage will be handled according to local requirements.  
Finance and insurance are addressed in the investigator and/or CRO agreements, as applicable.  
10.1.3  Informed consent process  
Participant’s informed consent must be obt ained and documented in accordance with local 
regulations, ICH -GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.  
Prior to obtaining informed consent, information should be given in a langu age and at a level of 
complexity understandable to the participant in both oral and written form by the investigator (or 
designee). Each participant will have the opportunity to discuss the study and its alternatives 
with the investigator.  
Prior to partici pation in the study, the ICF should be signed and personally dated by the 
participant, or her legal representative, and by the person who conducted the informed consent 
discussion (investigator or designee). The participant or her legal representative must  receive a 
copy of the signed and dated ICF. As part of the consent process, each participant must consent 
to direct access to her medical records for study -related monitoring, auditing, IRB/IEC review, 
and regulatory inspection.  
If the ICF is amended duri ng the study, the investigator (or the Sponsor, if applicable) must 
follow all applicable regulatory requirements pertaining to the approval of the amended ICF by 
the IRB/IEC and use of the amended form.  
All studies conducted at centers in the United State s must include the use of a Health Insurance 
Portability and Accountability Act Authorization form.  
The participant may withdraw her consent to participate in the study at any time. A participant is 
considered as enrolled in the study when she has signed t he ICF. An eCRF must not be started, 
nor may any study specific procedure be performed for a given participant, without having 
obtained her written consent to participate in the study.  
10.1.4  Data protection  
UCB staff (or designee) will affirm and uphold the part icipant’s confidentiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by the participant number 
assigned at Screening.  
The investigator agrees that representatives of UCB, its designee, representatives of the rel evant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of the 
participant’s primary medical records that directly concerns this study (including, but not limited 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 42 of 66 to admission/discharge summaries for hospital admi ssions occurring during a participant’s study 
participation and autopsy reports for deaths occurring during the study).  
The participant must be informed that her personal study -related data will be used by the 
Sponsor in accordance with local data protecti on laws. The level of disclosure must also be 
explained to the participant.  
The participant must be informed that her medical records may be examined by Clinical Quality 
Assurance auditors or other authorized personnel appointed by the Sponsor, by appropri ate 
IRB/IEC members, and by inspectors from regulatory authorities.  
10.1.5  Committees structure  
Not applicable.  
10.1.6  Data quality assurance  
All participant data relating to the study will be recorded on the eCRF unless transmitted to the 
Sponsor or designee electronic ally (eg, laboratory data). The investigator is responsible for 
verifying that data entries are accurate and correct by physically or electronically signing the 
eCRF.  
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF.  
The investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents.  
The Sponsor or designee is responsible for the data management of this study including quality 
checking of the data.  
Study monitors will perform ongoing source data verification to confirm that data entered into 
the eCRF by authorized site personnel are accurate, complete, and verifiable from source 
documen ts; that the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH -GCP, and all applicable regulatory requirements.  
All essential documents are to be retained by the investigator until at least 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have ela psed since the 
formal discontinuation of clinical development of CZP. These documents should be retained for 
a longer period, however, if required by the applicable regulatory requirement(s) or by an 
agreement with UCB ( Committee for Proprietary Medicinal Products  [CPMP]/ICH/135/95, 2002 
[Section  4.9.5]). The investigator will contact UCB for authorization prior to the destruction of 
any study records or in the event of accidental loss or destruction of any study records. The 
investigator will also notify U CB should he/she relocate or move the study -related files to a 
location other than that specified in the Sponsor’s trial master file.  
10.1.6.1  Electronic Case Report Form completion  
The investigator is responsible for prompt reporting of accurate, complete, and legible data in the 
eCRFs and in all required reports.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 43 of 66 Any change or correction to the eCRF after saving must be accompanied by a reason for the 
change.  
Corrections made after the investigator’s review and approval (by means of a 
password/electronic signat ure) will be reapproved by the investigator.  
The investigator should maintain a list of personnel authorized to enter data into the eCRF.  
Detailed instructions will be provided in the eCRF Completion Guidelines.  
10.1.6.2  Apps  
Not applicable.  
10.1.7  Source documents  
All so urce documents must be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typing, printing, or 
optical disc). They should not be obscured by correction fluid or have tempo rary attachments 
(such as removable self -stick notes).  
Source documents are original records in which raw data are first recorded. These may include 
hospital/clinic/general practitioner records, charts, diaries, x -rays, laboratory results, printouts, 
pharm acy records, care records, completed scales, quality of life questionnaires, or video, for 
example. Source documents should be kept in a secure, limited access area.  
Source documents that are computer generated and stored electronically must be printed for  
review by the monitor. Once printed, these copies should be signed and dated by the investigator 
and become a permanent part of the participant’s source documents. The investigator will 
facilitate the process for enabling the monitor to compare the conten t of the printout and the data 
stored in the computer to ensure all data are consistent.  
Electronic data records, such as Holter monitor records or electroencephalogram records, must 
be saved and stored as instructed by UCB (or designee).  
10.1.8  Study and site cl osure  
The Sponsor designee reserves the right to close the study site or terminate the study at any time 
for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all requ ired documents and study supplies 
have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the inten ded termination.  
Reasons for the early closure of a study site by the Sponsor or investigator may include but are 
not limited to:  
• Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health authorities, the Spon sor's procedures, or GCP guidelines  
• Inadequate recruitment of participants by the investigator  
• Discontinuation of further study medication development  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 44 of 66 10.1.9  Publication policy  
The results of this study may be published or presented at scientific meetings. If thi s is foreseen, 
the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. 
This allows the Sponsor to protect proprietary information and to provide comments.  
The Sponsor will comply with the requirements for publicatio n of study results. In accordance 
with standard editorial and ethical practice, the Sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data. In this case, a 
coordinating investigator will be designated by mutual agreement.  
Authorship will be determined by mutual agreement and in line with International Committee of 
Medical Journal Editors authorship requirements.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 45 of 66 10.2 Appendix 2: Clinical laboratory tests  
No clinical safety laboratory tests will be  performed in this study. CRP and albumin will be 
assessed as described in Section  8.9. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 46 of 66 10.3 Appendix 3: Adverse events – Definitions and procedures for 
recording, evaluating, follow -up, and reporting  
Definition of AE  
AE Definition  
• An AE is any untoward medical occurrence in a patient or clinical study participant, temporally 
associated with the use of study medication, whether or not considered related to the study 
medication.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the 
use of study medication.  
 
Events Meeting  the AE D efinition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other 
safety assessments (eg, radiological scans, vital signs measurements), including those that 
worsen from baseline, considered clinically significant in  the medical and scientific judgment 
of the investigator (ie, not related to progression of underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase in 
frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study medication administration even though it 
may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study medication or 
a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an 
intentional overdose taken with possible suicidal/self -harming intent. Such overdoses should be 
repor ted regardless of sequelae.  
• The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported 
as AE or SAE if they fulfil the definition of an AE or SAE. Also, "lack of efficacy" or "failure 
of expected pharmacological action" also constitutes an AE or SAE.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 47 of 66 Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments 
which are associated with the underlying disease, unless judged by the investigator to be more 
severe than expected for the participant’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the study participant’s 
condition.  
• Medical  or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the 
procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience 
admission to a hospital).  
• Anticipated day -to-day fluctuat ions of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (eg, hospitaliza tion for signs/symptoms of the disease under study, death due to 
progression of disease).  
A SAE is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
b. Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the participant was at 
risk of death at the time of the event. It does not refer to an event, which hypothetically might have 
caused death, if it were more severe.  
c. Requires inpatient hospitalization or prolongation of  existing hospitalization  
In general, hospitalization signifies that the participant has been detained (usually involving at least an 
overnight stay) at the hospital  or emergency ward for observation and/or treatment that would not have 
been appropriate in  the physician’s office or outpatient setting. Complications that occur during 
hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, 
the event is serious. When in doubt as to whether “hospitalization” o ccurred or was necessary, the AE 
should be considered serious.  
Hospitalization for elective treatment of a pre -existing condition that did not worsen from baseline is 
not considered an AE.  
d. Results in persistent disability/incapacity  
• The term disability me ans a substantial disruption of a person’s ability to conduct normal life 
functions.  
• This definition is not intended to include experiences of relatively minor medical significance 
such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma 
(eg, sprained ankle) which may interfere with or prevent everyday life functions but do not 
constitute a substantial disruption.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 48 of 66 e. Is a congenital anomaly/birth defect  
f. Important medical events  
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may not be immediately 
life-threatening or result in death or hospitalization but may jeopardize the participant or may 
require medical or surgical intervention to prevent one of the other outcomes listed in the 
above definition. These events should usually be considered serious.  
• Examples of such events include, but are not limited to, potential Hy’s law, invasive or 
malignant cancers, intens ive treatment in an emergency room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or 
development of drug dependency or drug abuse.  
Recording and Follow -Up of AE and/or SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospital progress notes, laboratory reports, and diagnostics reports) related 
to the event.  
• The investigator will then record all relevant AE/SAE informat ion in the eCRF.  
• It is not acceptable for the investigator to send photocopies of the participant’s medical records 
to UCB in lieu of completion of the UCB/AE/SAE eCRF page.  
• There may be instances when copies of medical records for certain cases are requested by 
UCB. In this case, all participant identifiers, with the exception of the participant number, will 
be redacted on the copies of the medical records before submission to UCB.  
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. Whenever possible, the diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during the study 
and assign it to 1 of the following categories:  
• Mild: An event that is easily tolerated by the participant, causing minimal discomfort and not 
interfering with everyday activities.  
• Moderate: An event that causes sufficient  discomfort and interferes with normal everyday 
activities.  
• Severe: An event that prevents normal everyday activities. An AE that is assessed as severe 
should not be confused with a SAE. Severe is a category utilized for rating the intensity of an 
event; a nd both AEs and SAEs can be assessed as severe.  
• An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe (eg, a severe AE may be 
either serious or not seri ous, depending on whether these criteria are also met).  
The National Cancer Institute Common Terminology Criteria for Adverse Events should be used as a 
supportive standardization instrument to evaluate AEs and SAEs but the final intensity grading by the 
investigator must be mild, moderate, or severe.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 49 of 66 Assessment of Causality  
• The investigator is obligated to assess the relationship between study medication and each 
occurrence of each AE/SAE.  
• A "reasonable possibility" of a relationship conveys that there  are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.  
• The investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomita nt therapy, and other risk factors, 
as well as the temporal relationship of the event to study medication administration will be 
considered and investigated.  
• The investigator will also consult the IB and/or Product Information, for marketed products, in 
his/her assessment.  
• For each AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to UCB. However, it is very important that the 
investigator always make an assessment of causality for every event before the  initial 
transmission of the SAE data to UCB.  
• The investigator may change his/her opinion of causality in light of follow -up information and 
send a SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
 
Follow -up of AEs and SAEs  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by UCB to eluci date 
the nature and/or causality of the AE or SAE as fully as possible. This may include additional 
laboratory tests or investigations, histopathological examinations, or consultation with other 
health care professionals.  
• An AE should be followed until it has resolved, has a stable sequelae, the investigator 
determines that it is no longer clinically significant, or the participant is lost to follow up. This 
follow -up requirement applies to AEs, SAEs, and AEs of special interest.  
• If a participant dies during participation in the study or during a recognized follow -up period, 
the investigator will provide UCB with a copy of any post -mortem findings including 
histopathology.  
• New or updated information will be recorded in the originally completed eCRF.  
• The investigator will submit any updated SAE data to UCB within 24 hours of receipt of the 
information.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 50 of 66 Reporting of SAEs  
SAE Reporting to UCB via an Electronic Data Collection Tool  
• The primary mechanism for reporting an SAE to  UCB will be the electronic data collection 
tool. 
• If the electronic system is unavailable for more than 24 hours, then the site will use the paper 
SAE data collection tool (see next section).  
• The site will enter the SAE data into the electronic system as s oon as it becomes available.  
• After the study is completed at a given site, the electronic data collection tool will be taken off -
line to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or receives updated data on a 
previously reported SAE after the electronic data collection tool has been taken off -line, then 
the site can report this information on a paper SAE form (see next section) or to the medical 
monitor by telephone.  
• Contacts for SAE reporting can be found in the section on SERIOUS ADVERSE EVENT 
REPORTING . 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 51 of 66 10.4 Appendix 4: Contraceptive guidance and collection of 
pregnancy information  
Definitions  
All study participants will be pregnant females (IC 3). 
• The investigator will collect pregnancy information on any pregnant female participating in 
this study. The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on the participant and t he neonate, and the 
information will be forwarded to the Sponsor. Generally, the follow -up will be at least 
12 weeks after the delivery date. In certain circumstances, UCB may request that follow up is 
continued for a period longer than 12 weeks.  Any termi nation of pregnancy will be reported, 
regardless of fetal status (presence or absence of anomalies) or indication for the procedure.  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregna ncy will be reported as an AE or SAE. A spontaneous 
abortion is always considered to be an SAE and will be reported as such. Any post -study 
pregnancy related SAE considered reasonably related to CZP by the investigator will be 
reported to the Sponsor as de scribed in Section  8.3.5 . While the investigator is not obligated 
to actively seek this information in former study participants, he or she may lear n of an SAE 
through spontaneous reporting.  
Pregnancy and neonatal outcomes will be followed via Pregnancy Report and Outcome Forms 
which is the standard methodology for follow -up of all reported pregnancies and is a routine 
process unrelated to study proce dure.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 52 of 66 10.5 Appendix 5: Genetics  
Not applicable.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 53 of 66 10.6 Appendix 6: Liver safety – Suggested actions and follow -up 
assessments  
No safety laboratory assessments will be performed in this study; as such, no evaluation of liver 
safety will be conducted.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 54 of 66 10.7 Appendix 7: Medica l device incidents – Definition and 
procedures for recording, evaluating, follow -up, and reporting  
Not applicable.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 55 of 66 10.8 Appendix 8: Rapid alert procedures  
Not applicable.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 56 of 66 10.9 Appendix 9: Country -specific requirements  
Not applicable.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 57 of 66 10.10  Appendix 10: Abbreviations and trademarks  
AE adverse event  
BCG  Bacillus Calmette –Guérin  
BMI  body mass index  
CI confidence interval  
CPMP  Committee for Proprietary Medicinal Products  
CRO  contract research organization  
CRP  C-reactive protein  
CV Coefficient of variation  
CZP certolizumab pegol  
eCRF  electronic Case Report Form  
ES Enrolled Set  
EWD  Early Withdrawal or Discontinuation  
Fab antibody fragment  
GCP  Good Clinical Practice  
HBsAg  Hepatitis B surface antigen  
IB Investigator’s Brochure  
IC inclusion criterion  
ICF Informed Consent Form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
IGRA  interferon gamma release assay  
IMP investigational medicinal product  
IRB Institutional Review Board  
LLOQ  lower limit of quantification  
MedDRA  Medical Dictionary for Regulatory Activities  
NTM  nontuberculous mycobacterial  
PK pharmacokinetics  
PK-PPS Pharmacokinetic Per -Protocol Set  
Q2W  every 2 weeks  
Q4W  every 4 weeks  
Q8W  every 8 weeks  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 58 of 66 RNA  ribonucleic acid  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
SAS statistical analysis system  
SD standard deviation  
SFU Safety Follow -up 
SS Safety Set  
TB tuberculosis  
TEAE  treatment -emergent adverse event  
TST tuberculin skin test  
ULN  upper limit of normal  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 59 of 66 10.11  Appendix 11: Protocol amendment history  
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents.  
Amendment 1 (Aug 29 2019)  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 60 of 66  Amendment 1 (29  Aug 2019 )  
Overall Rationale for the Amendment  
The purpose of this substantial amendment is to implement pre -review feedback received from the Central IRB US (Advarra) dated 
31 Jul 2019.  
The first version of the protocol was not formally submitted.  
Section # and Name  Description of Ch ange  Brief Rationale  
Title page  EudraCT number 2019 -003410 -13 has been 
added.  EudraCT number was omitted in original 
protocol.  
Section 4.1  Previous text:  
This study is considered interventional due to 
the collection of blood samples from the 
women, whic h is not part of routine clinical 
practice. However, it is noninterventional 
regarding treatment with CZP and will only 
include pregnant women who decided with 
their treating physician to continue treatment 
with CZP prior to being recruited for and 
enrolle d in the study. Study participants who 
start CZP treatment after confirmation of 
pregnancy will not be eligible to participate in 
the study. Study participants are responsible 
for procuring their own supply of commercial 
CZP as it is not provided as part o f the study.  
New text:  
The study is interventional due to the 
additional collection of blood samples from 
women. However, all other study 
assessments are part of routine clinical 
practice (with the exception of the diary), 
and the  decision to continue/dis continue 
CZP therapy during pregnancy will be 
made between the participant and her To clarify the text a nd to describe further that 
there is no intention to interfere with treating 
physician’s decisions on the care of their 
patient  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 61 of 66  treating physician, taking into account the 
potential risks to the mother and the 
benefits of CZP therapy, and according to 
the applicable local label.  
Section 6.5  Added text: Unless otherwise prohibited per 
protocol exclusion criteria, study participants 
are permitted to continue on their prescribed 
medical therapy for the disease in accordance 
with the instructions of their treating physician  To clarify the intention is for study 
participants to continue their prescribed 
therapy for their disease unless prohibited per 
protocol exclusion criteria.  
Section 6.5.2  Section heading changed from:  
Prohibited concomitant treatments 
(medications and therapies)  
 
To: 
Concomitant medications that lead to study 
withdrawal  To further clarify that the intention is not to 
interfere with the physician’s decision.  
 
 
 
Section 6.5.2  Previous text:  
The study participant must not participate in 
any other interventional clinical study or 
receive any unauthorized medication 
throughout the Study Period.  
 
New text:  
The study participant must not p articipate 
in any other interventional clinical study or 
receive any unauthorized medication 
throughout the study period. Non -
Interventional study (NIS) participation is 
allowed.  To allow for non -interventional study 
participation where applicable.  
Previous text:  
There are certain exclusion criteria and 
withdrawal criteria associated with To further clarify that there is no intention to 
interfere with the treating physician’s decision 
on treatment of their patient and to add 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 62 of 66  concomitant medication use; to protect the 
safety of the study participant and to ensure 
robust and interpretable data, there is no 
intention to interfere with the  physician’s 
decision on treatment.  
The following concomitant medications are 
prohibited during the study:  
 
New text:  
There are no specific prohibited 
concomitant medications in this study, as it 
is not the intention to interfere with the 
physician’s dec ision on treatment.  
However, there are certain exclusion 
criteria and withdrawal criteria associated 
with concomitant medication use to ensure 
robust and interpretable data.  These 
criteria include:.   language to describe that the use of any 
medications listed in section 6.5.2 would 
result in withdrawal from the study.  
Section 7.2  Previous text:  
3. Participant takes proh ibited concomitant 
medications as defined in this protocol 
(Section 6.5.2).  
New Text:  
3. Participant takes prohibited  concomitant 
medications that lead to study withdrawal  as 
defined in this protocol (Section 6.5.2).  To align the withdrawal criteria with updates 
made in Section 6.5.2  
Section 8  Previous text:  
Immediate safety concerns should be 
discussed with the sponsor immediately upon 
occurrence or awareness to determine if the 
participant should continue or discontinue 
CZP.   
 To clarify it is the treating physician’s 
responsibility to determine if the patient 
continues or is discontinues treatment.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 63 of 66  New text  
It will be the r esponsibility of the treating 
physician to determine if the participant 
should continue or discontinue treatment.   
The sponsor should be informed 
immediately regarding safety concerns 
upon occurrence or awareness to determine 
if the participant should con tinue or 
discontinue participation in the study.  
Section 8.3.5  Previous text:  
Women who become pregnant while taking 
CZP, and choo se not to participate in the 
study, will still have their pregnancy followed 
per normal UCB guidance on pregnancy 
reporting.  
 
New Text:  
Information regarding collection of 
pregnancy -related data is located in 
Appendix 4 section 10.4  To align text with Section 10.4  
Section 8.5  Previous text:  
Excessive dosing (beyond that prescribed in 
the protocol and including overdose) should 
be recorded in the Drug Accountability 
module of the eCRF  
 
New text:  
Excessive dosing (beyond that prescribed 
per the local label) will be recorded by the 
study participant in the diary and also 
recorded in the eCRF.  The dosing 
documentation will be reviewed and To clar ify that dosing will be captured by the 
study participant in the diary and verified by 
the investigator and/or home health nurse in 
addition to documented in the eCRF.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
  
Confidential  Page 64 of 66  verified by the investigator and/or home 
health nurse  
Deleted text:  
Decisions regarding dose interruptions or 
modifications will be made by the investigator 
in consultation with the Medical Monitor 
based on the clinical evaluation of the 
participant.  To clarify that dosing decisions are the 
responsibility of the treating physician  
Section 10.4  Previous text:  
Women who become pregnant while ta king 
CZP, and choose not to participate in the 
study, will still have their pregnancy followed 
per normal UCB guidance on pregnancy 
reporting.  
New text:  
Pregnancy and neonatal outcomes will be 
followed via Pregnancy Report and 
Outcome Forms which is the st andard 
methodology for follow -up of all reported 
pregnancies and is a routine process 
unrelated to study procedure.  
 To clarify how pregnancy and neonatal 
outcomes will be followed -up. 
Throughout  Change of "study treatment" to "CZP")  Deleted reference to ‘study treatment’ and 
clarified that this refers to CZP.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
   
Confidential  Page 65 of 66  11 REFERENCES  
CIMZIA© Prescribing information accessed at 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125160s270lbl.pdf on 15  Jul 2019.  
CPMP/ICH/135/95 Note for guidance on Good Clinical Practice (EMEA) Jul 2002.  
Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during 
pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann 
Rheum Dis. 2018:77(2):228 -233. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   30 Aug 2022  
Clinical Study Protocol  Certolizumab pegol  UP0085  
   
Confidential  Page 66 of 66  SPONSOR DECLARATION  
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
Approval Signatures
Name: UP0085-protocol-amend-2
Version: 1 . 0
Document Number: CLIN-000202273
Title: A postmarketing, multicenter, longitudinal, prospective, pharmacokinetic, Phase 1B study
Approved Date: 31 Aug 2022
Document Approvals
Approval
Verdict: ApprovedName: 
Capacity: Clinical
Date of Signature: 30-Aug-2022 21:22:47 GMT+0000
Approval
Verdict: ApprovedName: 
Capacity: Medical
Date of Signature: 31-Aug-2022 08:07:51 GMT+0000
Approval
Verdict: ApprovedName: 
Capacity: Clinical
Date of Signature: 31-Aug-2022 15:32:42 GMT+0000
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.